Literature DB >> 8626138

Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis.

L A King1, T Okagaki, D G Gallup, L B Twiggs, M J Messing, L F Carson.   

Abstract

In spite of extensive research, the behavior of granulosa cell ovarian tumors remains unpredictable and is complicated by the lack of prognostic factors in early-stage disease. Forty patients with granulosa cell tumors were identified from tumor registries and data were analyzed for patient outcome. Mitotic count and nuclear atypia were determined at time of histological review. Paraffin-embedded archival tumor tissues from 32 of 40 patients were available, and immunohistochemical testing for Ki-67, c-myc, p21-ras, c-erbB2, and p53 was performed on archival tissues. Results were correlated with patients' outcome. Mitotic count and Ki-67 were found to be negatively associated with survival in granulosa cell tumors. Nuclear atypia, c-myc, p21-ras, c-erbB2, and p53 were not found to be of prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626138     DOI: 10.1006/gyno.1996.0130

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Granulosa Cell Tumors: Novel Predictors of Recurrence in Early-stage Patients.

Authors:  Sharif Sakr; Eman Abdulfatah; Sumi Thomas; Zaid Al-Wahab; Rafic Beydoun; Robert Morris; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay
Journal:  Int J Gynecol Pathol       Date:  2017-05       Impact factor: 2.762

Review 2.  Low-grade epithelial ovarian cancer: what a radiologist should know.

Authors:  Sherif Elsherif; Sanaz Javadi; Chitra Viswanathan; Silvana Faria; Priya Bhosale
Journal:  Br J Radiol       Date:  2019-01-31       Impact factor: 3.039

3.  Granulosa cell tumours: a study of 37 cases.

Authors:  C Nirmala; Kalpana S Dave; Anjana Chauhan; Ronak P Bhansali; Ruchi Arora
Journal:  J Obstet Gynaecol India       Date:  2012-08-01

4.  Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor.

Authors:  Mayra Tsoi; Marie-Noëlle Laguë; Alexandre Boyer; Marilène Paquet; Marie-Ève Nadeau; Derek Boerboom
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

5.  The C-terminal common to group 3 POTES (CtG3P): a newly discovered nucleolar marker associated with malignant progression and metastasis.

Authors:  Samantha M Redfield; Jinghe Mao; He Zhu; Zhi He; Xu Zhang; Steven A Bigler; Xinchun Zhou
Journal:  Am J Cancer Res       Date:  2013-06-20       Impact factor: 6.166

6.  Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Paul G Farnworth; Craig Harrison; Peter Nicholls; Yao Wang; Ruth M Escalona; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2009-01-22

7.  In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.

Authors:  A G Emanuels; J Koudstaal; M P Burger; H Hollema
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

8.  The new molecular biology of granulosa cell tumors of the ovary.

Authors:  Nicolas Kalfa; Reiner A Veitia; Bérénice A Benayoun; Brigitte Boizet-Bonhoure; Charles Sultan
Journal:  Genome Med       Date:  2009-08-25       Impact factor: 11.117

9.  Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature.

Authors:  Sakina Sekkate; Mouna Kairouani; Badr Serji; Adnane Tazi; Hind Mrabti; Saber Boutayeb; Hassan Errihani
Journal:  World J Surg Oncol       Date:  2013-06-18       Impact factor: 2.754

10.  Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary.

Authors:  Hans-Ullrich Völker; Sabine Engert; Andreas Cramer; Melanie Schmidt; Ulrike Kämmerer; Hans-Konrad Müller-Hermelink; Stefan Gattenlöhner
Journal:  Diagn Pathol       Date:  2008-07-09       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.